Salbutamol and lymphocyte entry to lymph nodes
Animal study · CD45.2+ WT mice [1]
In CD45.2+ WT mice, Salbutamol was administered at 12 mg/kg by i.v. injection immediately before cell transfer. Compared with saline, Salbutamol did not affect lymphocyte entry to LNs.
| Endpoint | Reported result | Reference |
|---|---|---|
| number of CD4+ T cells (CD4+) or B cells (CD19+) recovered in each recipient per 106 transferred CD45.1+ populations | Reported result did not affect lymphocyte entry to LNs | [1] |
Conditions shared by the study groups
- Route
- i.v. injection
- Treatment course
- immediately before cell transfer
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Salbutamol 12 mg/kg | saline | did not affect lymphocyte entry to LNs | [1] |
- Salbutamol 12 mg/kg
- Model: CD45.2+ WT mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Salbutamol
The paper names Salbutamol without stating the salt or form; not verified as the sulfate form supplied as A10819. No dose conversion or lot validation.
RESULTS > Lymphocyte egress from LNs is inhibited by β2AR stimulation (S19); MATERIALS AND METHODS > Untitled > Lymphocyte entry to LN. (S169); Figure 2. legend (S218, S219)
number of CD4+ T cells (CD4+) or B cells (CD19+) recovered in each recipient per 106 transferred CD45.1+ populations: number of CD4+ T cells (CD4+) or B cells (CD19+) recovered in each recipient per 106 transferred CD45.1+ populations; comparator: saline — RESULTS > Lymphocyte egress from LNs is inhibited by β2AR stimulation (S19); Figure 2. legend (S219)
Salbutamol 12 mg/kg · RESULTS > Lymphocyte egress from LNs is inhibited by β2AR stimulation (S19); MATERIALS AND METHODS > Untitled > Lymphocyte entry to LN. (S169)